Social Behavior – Page 7

Bayer Prepares for Critical Challenges Amid Xarelto Decline

5 months ago talkbio0Tagged Bayer, competition, decline, Drug Industry, earnings, JPM25, Legal patent, strategic plans, Xarelto

Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25

RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment

5 months ago talkbio0Tagged ARMGO, biotech company, Cardiovascular Diseases, Changing, Heart failure, Leadership, Pharma, Rycals, RyCarma, skeletal muscle diseases

RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.

GSK Advances Liver Disease Research and Biotech CEO Sisterhood Grows Influence

5 months ago talkbio0Tagged biotech, CEO, Drug Industry, JPM25, Liver diseases, sisterhood, SmithKline Beecham, Women

GSK, liver disease, Biotech CEO Sisterhood, JPM25, pharmaceutical industry, women in biotech

Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline

5 months ago talkbio0Tagged 2025, competition, cost-cutting measures, COVID19 (disease), decline, Market, Moderna, Vaccination, Vaccines

Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.

BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

5 months ago talkbio0Tagged Agreement, BioNTech, COVID19 (disease), Disputes, NIH Mouse, Pfizer, Royalty, settlement, UPenn, Vaccines

BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements

Celebrating Visionaries: Insights from the 2024 Fierce 50 Honorees

6 months ago talkbio0Tagged 2024, Advocacy, Biopharma, Fierce, Health Equity, healthcare innovation, honorees

Fierce 50, 2024 Honorees, Healthcare Innovation, Biopharma, Health Equity, Patient Advocacy

Applied Therapeutics Undergoes Leadership Changes Amid FDA Rejection and Regulatory Challenges

6 months ago talkbio0Tagged Changing, disease drug, Govorestat, Leadership, regulatory, Rejection, United States Food and Drug Administration

Applied Therapeutics, leadership changes, FDA rejection, rare disease drug, govorestat, regulatory challenges

Bristol Myers Squibb Partners with BioArctic in $100M Alzheimer’s Deal

6 months ago talkbio0Tagged Alzheimer 's disease, BioArctic, Collaboration, Leqembi, Myers, squibb

Bristol Myers Squibb, BioArctic, Leqembi, Alzheimer’s disease, collaboration, $100M upfront payment

Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations

6 months ago talkbio0Tagged Autoimmune Diseases, Biotechnology, biotherapeutics, Candid, Collaboration, engagers, Nona Biosciences, T-Lymphocyte

T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

6 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition